20
May
2021
GSK Persists with Vaccines, ASCO Abstracts, & Biogen Gene Therapy Fizzles
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
May
2021
Pfizer Advances to Adolescents, Xontogeny’s New Fund & Rekindling Curiosity
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
May
2021
Biden Threatens Patents, Vaccines Shine, & Biogen’s Pricing Predicament
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
May
2021
Startup Profiles: Perlmutter Bets on Super Microscopy; Foresite’s Precision Immunology
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
May
2021
Spotting Trends and Starting Edgy Companies: Daphne Zohar on The Long Run
Today’s guest on The Long Run is Daphne Zohar. Daphne is the founder and CEO of Boston-based Puretech Health. Puretech has been around since 2005, seeking to capitalize on some of the big trends in biotech. It started out seeking to test concepts from academic labs that could be the basis for new biotech companies – what’s now commonly called... Read More
29
Apr
2021
J&J Back After Pause, Sanofi Aids Moderna, and a Flood of Women Join Biotech Boards
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
21
Apr
2021
Versant Ventures, Sticking With its Knitting, Raises $950M for Early Stage Biotechs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
19
Apr
2021
Partnering in a World of Scientific Abundance: James Sabry on The Long Run
Today’s guest on The Long Run is James Sabry. James is the Global Head of Pharma Partnering for Roche. He’s based in Basel, Switzerland. He did his PhD in neuroscience at UCSF, and spent the bulk of his career in biotech in California. After leading a couple of startups, he joined Genentech in 2010 as vice president of partnering. It... Read More
9
Apr
2021
Timmerman Traverse for LSC: A Biotech Community Drive to Fight Poverty
Like many people, I’m itching to get outside. Today, I’m excited to announce a new outdoor experience for a good cause: The Timmerman Traverse for Life Science Cares. It’s a Presidential Traverse hike scheduled for Sept. 13-15, 2021. A fantastic group of 20 biotech leaders — 10 women and 10 men — will hit the trails. We’ll cover the iconic... Read More
1
Apr
2021
Pfizer’s Vaccine Passes Kid Test, J&J’s Costly Error, and FTC Challenges Illumina
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
30
Mar
2021
Amgen Acquires Rodeo, Lean Startup With Dual Mechanism for Crohn’s, Colitis
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
29
Mar
2021
Writing with DNA at Scale: Emily Leproust on The Long Run
Today’s guest on The Long Run is Emily Leproust. Emily is the co-founder and CEO of South San Francisco-based Twist Bioscience. It’s a DNA synthesis company. It uses a silicon-based system to “write” in the language of DNA – that is, make synthetic genes to test ideas in a lab, or to perform some basic biomedical or industrial workhorse function.... Read More
25
Mar
2021
A Glimpse Into a Price-Controlled Future
Imagine if H.R. 3 — the drug price-control bill that has significant support in the House of Representatives — were to become law. What would it look like if some of the bill’s provisions, like indexing US prices to 120 percent of prices in Europe, were enacted? How would entrepreneurs adapt? What types of drug discovery programs might be prioritized,... Read More
22
Mar
2021
AZ Tells Us Its Vaccine is OK. Rebuilding Trust Will Take a While
Credibility can be lost in a heartbeat. It can take years to rebuild. That maxim kept running through the back of my mind when reading the press release on the AstraZeneca Phase III clinical trial conducted with 32,449 participants in the US, Peru and Chile, in partnership with the NIH’s COVID-19 Prevention Network. The top line was encouraging — 79... Read More
18
Mar
2021
Burnout Risk Is High. People Need a Break
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Mar
2021
AZ’s Vaccine Mess, Rubius Infiltrates Solid Tumors, & Insitro’s $400M Haul
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
Mar
2021
Software for the Cell & Gene Therapy Wave: Vineti’s Amy DuRoss on The Long Run
Today’s guest on The Long Run is Amy DuRoss. Amy is the co-founder and CEO of San Francisco-based Vineti. The company provides software to manage the delicate logistical dance for cell and gene therapies. Vineti has raised about $115 million in three venture rounds of financing. Its backers include Cardinal Health, the big medical distributor, as well as traditional venture... Read More
11
Mar
2021
Novavax Shines, VIR Antibody Stays in the Game, and CDC Lightens Up
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Mar
2021
Signs of Life: Merck-Ridgeback COVID-19 Antiviral and Sanofi Universal Flu Vaccine
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Mar
2021
Science Policy Chat: Join Rep. Auchincloss and Me on Clubhouse Mar. 10
Science is poised for a comeback in the public mind. Most can agree that science, after years of getting beaten up, is leading us out of the crisis. It’s a source of national competitive advantage. This creates an opportunity to double down on investments, to test new ways of working, to shake some things up that need shaking. Mark your... Read More